BR0208681A - Compostos de peptìdeos e uso dos mesmos - Google Patents

Compostos de peptìdeos e uso dos mesmos

Info

Publication number
BR0208681A
BR0208681A BR0208681-6A BR0208681A BR0208681A BR 0208681 A BR0208681 A BR 0208681A BR 0208681 A BR0208681 A BR 0208681A BR 0208681 A BR0208681 A BR 0208681A
Authority
BR
Brazil
Prior art keywords
identification
cells
liposomes
cancer
tumor cells
Prior art date
Application number
BR0208681-6A
Other languages
English (en)
Inventor
Oula Penate Medina
Erkki Koivunen
Paavo Kinnunen
Original Assignee
Ctt Cancer Targeting Tech Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ctt Cancer Targeting Tech Oy filed Critical Ctt Cancer Targeting Tech Oy
Publication of BR0208681A publication Critical patent/BR0208681A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSTOS DE PEPTìDEOS E USO DOS MESMOS". A presente invenção refere-se a terapia com alvo no cancer e refere-se especificamente, ao uso de pequenos inibidores da metaloproteinase da matriz melhorando a capacidade de identificação pelos lipossomos das células do cancer, e ao aumento da capacidade de identificação das referidas células pelos lipossomos. A invenção provê desse modo um método para tratar o câncer, bem como um método para melhorar a identificação das células de tumores pelos lipossomos, um método para aumentar a capacidade de identificação das células de tumores pelos lipossomos, e um método para liberação selecionada dos agentes quimioterapêuticos pelos lipossomos dentro das células de tumores.
BR0208681-6A 2001-03-26 2002-03-26 Compostos de peptìdeos e uso dos mesmos BR0208681A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20010620A FI113840B (fi) 2001-03-26 2001-03-26 Matriisi-metalloproteinaasi-inhibiittorien käyttö liposomien kohdentamisessa
PCT/FI2002/000252 WO2002076491A1 (en) 2001-03-26 2002-03-26 Liposome targeting of matrix metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
BR0208681A true BR0208681A (pt) 2004-03-30

Family

ID=8560842

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0208681-6A BR0208681A (pt) 2001-03-26 2002-03-26 Compostos de peptìdeos e uso dos mesmos

Country Status (23)

Country Link
US (2) US20040213833A1 (pt)
EP (1) EP1372694B1 (pt)
JP (1) JP2004529127A (pt)
KR (1) KR20040000414A (pt)
CN (1) CN1250279C (pt)
AT (1) ATE331526T1 (pt)
BR (1) BR0208681A (pt)
CA (1) CA2441227A1 (pt)
CZ (1) CZ20032805A3 (pt)
DE (1) DE60212814T2 (pt)
DK (1) DK1372694T3 (pt)
EE (1) EE200300467A (pt)
ES (1) ES2266458T3 (pt)
FI (1) FI113840B (pt)
HU (1) HUP0303649A3 (pt)
IL (1) IL158114A0 (pt)
NO (1) NO20034280L (pt)
NZ (1) NZ528043A (pt)
PL (1) PL365248A1 (pt)
RU (1) RU2003131332A (pt)
SK (1) SK12982003A3 (pt)
WO (1) WO2002076491A1 (pt)
YU (1) YU74703A (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7279150B2 (en) 2002-01-24 2007-10-09 Barnes-Jewish Hospital Chelating agents with lipophilic carriers
IL152609A0 (en) * 2002-11-03 2003-06-24 Hapto Biotech Inc Liposomal compositions comprising haptotactic peptides and uses thereof
CN1314704C (zh) * 2002-11-20 2007-05-09 中国人民解放军军事医学科学院放射与辐射医学研究所 基质金属蛋白酶2的小肽抑制剂
EP1594550A4 (en) * 2003-01-24 2007-07-11 Barnes Jewish Hospital CHELATBILDNER WITH LIPOPHILES
FI115035B (fi) * 2003-05-02 2005-02-28 Ctt Cancer Targeting Tech Oy In vivo -kuvantaminen käyttäen peptidijohdannaisia
FI20031528A0 (fi) * 2003-10-17 2003-10-17 Ctt Cancer Targeting Tech Oy Terapeuttinen liposomikoostumus ja menetelmä sen valmistamiseksi
FI20040572A0 (fi) * 2004-04-23 2004-04-23 Ctt Cancer Targeting Tech Oy Matriisi-metalloproteinaasin aktiviteetin inhibiittorit
FI20040682A0 (fi) * 2004-05-14 2004-05-14 Ctt Cancer Targeting Tech Oy Tuumorien ja mestastaasien kuvantaminen käyttäen gelatinaasiin targetoituvaa peptidiä
FR2870741B1 (fr) 2004-05-25 2008-03-14 Coletica Sa Phase lamellaires hydratees ou liposomes, contenant une monoamine grasse ou un polymere cationique favorisant la penetration intercellulaire, et composition cosmetique ou pharmaceutique la contenant.
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
CN101616692B (zh) * 2006-07-06 2013-05-08 纽约市哥伦比亚大学信托人 用于血管造影术的多色的不同大小的颗粒
CN102114000B (zh) * 2009-12-31 2013-08-21 复旦大学 一种载药的共输送脂质纳米递药系统
US8871189B2 (en) * 2011-11-30 2014-10-28 Mallinckrodt Llc MMP-targeted therapeutic and/or diagnostic nanocarriers
US11339209B2 (en) 2016-11-14 2022-05-24 Novartis Ag Compositions, methods, and therapeutic uses related to fusogenic protein minion

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158760A (en) * 1990-05-30 1992-10-27 Board Of Regents, The University Of Texas System 99m TC labeled liposomes
IL130823A (en) * 1996-10-15 2005-12-18 Elan Pharm Inc Peptide-lipid conjugates, liposomes drug delivery
FI980604A0 (fi) * 1998-03-18 1998-03-18 Univ Helsinki Licensing Nya matrismetalloproteinasinhibitorer och -regulatorer

Also Published As

Publication number Publication date
NO20034280L (no) 2003-11-25
WO2002076491A1 (en) 2002-10-03
CA2441227A1 (en) 2002-10-03
DK1372694T3 (da) 2006-10-30
US20040213833A1 (en) 2004-10-28
FI113840B (fi) 2004-06-30
ES2266458T3 (es) 2007-03-01
CZ20032805A3 (cs) 2004-06-16
EP1372694B1 (en) 2006-06-28
US20050271588A1 (en) 2005-12-08
ATE331526T1 (de) 2006-07-15
DE60212814T2 (de) 2007-02-08
CN1250279C (zh) 2006-04-12
EE200300467A (et) 2003-12-15
KR20040000414A (ko) 2004-01-03
NZ528043A (en) 2005-08-26
DE60212814D1 (de) 2006-08-10
CN1531439A (zh) 2004-09-22
EP1372694A1 (en) 2004-01-02
HUP0303649A2 (hu) 2004-01-28
FI20010620A0 (fi) 2001-03-26
PL365248A1 (en) 2004-12-27
IL158114A0 (en) 2004-03-28
RU2003131332A (ru) 2005-04-10
JP2004529127A (ja) 2004-09-24
HUP0303649A3 (en) 2005-12-28
SK12982003A3 (sk) 2004-08-03
NO20034280D0 (no) 2003-09-25
FI20010620A (fi) 2002-09-27
YU74703A (sh) 2006-05-25

Similar Documents

Publication Publication Date Title
BR0208681A (pt) Compostos de peptìdeos e uso dos mesmos
BR0209646A (pt) genes expressos em cáncer de mama como alvos de prognósticos e terapêuticos
BRPI0411526A (pt) vìrus de vaccinia e outros microrganismos recombinates modificados e usos dos mesmos
WO2001072962A3 (en) Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
BRPI0315666B8 (pt) dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos
WO2004079368A3 (en) Markers for colorectal cancer
BR9807418A (pt) Terapia de gene supressor de tumor combinado e quimioterapia no tratamento de neoplasmas
AU9016998A (en) Methods and compositions for overcoming resistance to biologic and chemotherapy
WO2000018439A3 (de) Verwendung von neoangiogenese-markern für diagnose und therapie von tumoren
BRPI0416156A (pt) uso de tienopirimidinas
BR0315942A (pt) Tratamento de doenças e condições mediadas pelo aumento de fosforilação
EA200300934A1 (ru) Агенты и способы, предназначенные для лечения опухолевых заболеваний
ES2187648T3 (es) Metodo para la administracion de farmacos para terapia genica.
WO2004013313A3 (en) Antisense nucleic acids
ATE414100T1 (de) Zielgerichtete ligande gegen peyer's flecke- und/oder m-zellen
PT1267915E (pt) Metodos para tratar doencas com proteina c activada
ATE489971T1 (de) Ionaustausch-tumor zielausrichtung
SE0100684D0 (sv) New subject-matter
HUP9900011A2 (hu) A GAX protein alkalmazása rák kezelésére
BR0017046A (pt) Uso de azóis para prevenção de câncer de pele
BR0313550A (pt) modulação "antisense" da expressão de sintetase 1 de acil-coa
WO2002101076A3 (en) Methods for targeted expression of therapeutic nucleic acid
ATE537838T1 (de) Kombinationstherapie mit kloretazin(tm)
DE69938501D1 (de) Verwendung von prohibitin-rns in krebsbehandlung
WO2002008456A3 (de) Verfahren zur identifizierung metastasierender tumorzellen

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A E 7A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2029 DE 24/11/2009.